BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines collaboration & Other Revenue ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations (XBRL)
Latest, Q2 2026
25.3
Period ended Jun 30, 2026
Change on a year earlier
+91.7%
13.2 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
28
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up collaboration & other revenue ($m)
- Collaboration & Other Revenue — United States ($M)15.6 · Q2 2026
- Collaboration & Other Revenue — China ($M)6.30 · Q2 2026
- Collaboration & Other Revenue — Europe ($M)0.30 · Q2 2026
- Collaboration & Other Revenue — Rest of World ($M)–
- Collaboration R&D Service Revenue ($M, FY16–FY22)59 · Q3 2023
- Collaboration R&D Cost Reimbursement Revenue ($M, FY16–FY21)0 · Q4 2020
- Collaboration Right-to-Access IP Revenue ($M, FY19–FY22)52 · Q3 2023
- Other Collaboration Revenue ($M, FY17–FY22)3 · Q3 2023
Cite this data
StockData. (2026). BeOne Medicines Collaboration & Other Revenue ($M) ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rev_collab_total
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.